STOCK TITAN
  1. Home
  2. Financials
  3. IPHYF
  4. EPS (Diluted)

Innate Pharma (IPHYF) EPS by Year

IPHYF OTC

Innate Pharma lost $0.65 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 9 fiscal years, from 2017 to 2025.

FY2025 annual
EPS (Diluted) -$0.65
YoY n/m
5Y CAGR n/m
Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

IPHYF EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
EPS (Diluted)-$0.65n/m-$0.63n/m-$0.10n/m-$0.78n/m-$0.75n/m-$0.99n/m-$0.35-707.3%$0.06n/m-$1.07

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Innate Pharma financials

Frequently Asked Questions

Innate Pharma lost $0.65 per diluted share in fiscal year 2025.

Innate Pharma (IPHYF) reported a loss of $0.63 per diluted share in fiscal year 2024 and a loss of $0.65 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Across the 9 fiscal years this page covers, Innate Pharma (IPHYF) diluted earnings per share went from -$1.07 in fiscal year 2017 to -$0.65 in fiscal year 2025.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Innate Pharma (IPHYF) reported on that line in every period on record.